Across the biopharmaceutical industry, the transition from traditional constructs such as large stainless-steel factories, batch manufacturing and paper-based recording systems to modular facilities, single-use technologies, continuous manufacturing and electronic systems is picking up pace. It’s easy to see why: the benefits of greater agility and responsiveness for capacity planning, significantly reduced manufacturing costs and improved product quality speak for themselves. This is particularly important for the emerging field of advanced therapeutics such as cell and gene therapies. Yet despite all the scientific and technological advances, the issue of how to effectively manage data, workflows and knowledge across the development lifecycle remains a stumbling block.
Join this free webinar where experts will discuss what is needed to address the current industry challenges and transform the future of biomanufacturing, including:
- What does digital transformation mean for bioprocess development
- Cell and gene therapies: how do their challenges compare to traditional biologics?
- Balancing the requirement for flexibility, agility and responsiveness with standardized data capture and reporting
- Data standards: why have previous attempts failed and what are the most promising new developments
- Breaking down the barriers between research, development and manufacturing
- Improving reproducibility and increasing automation
Dr. Eliot Randle, Managing Partner and Co-Founder, Digital Lab Consulting
Dr. Eliot Randle MBA is a managing partner and cofounder of Digital Lab Consulting, an independent strategic consulting company that enables organisations to transform their business through better use of informatics. With more than 20 years’ experience in the biopharmaceutical industry across the entire value chain from R&D to manufacturing and clinical, Eliot has a track record of delivering business transformation for clients.Message Presenter
Claire Hill, Solutions Support Manager, IDBS
Claire Hill helps ensure that customers realize the full benefit and transformational impact of IDBS’ solutions. Claire has a Master of Science in Biochemical Engineering and an MBA and previously worked as a financial analyst for IBM and as a bioprocess consultant for BioPharm Services.Message Presenter
Who Should Attend?
This webinar will be suitable for senior-level pharma R&D scientists and leaders involved in:
- Process Development
- Analytical Method Development/QC
- Tech Transfer/GMP Manufacturing
- Regulatory Compliance
- Project Management
- Operational Oversight
What You Will Learn
Participants will learn about:
- How digital technologies can transform bioprocess development
- What cell and gene therapy companies can learn from biologics
- How to break down the communication barriers between R&D and manufacturing
- Why software can help improve reproducibility in process development
Providing the world’s best cloud-based, research and development data management technology and solutions in a scientific informatics platform.
IDBS is a leading global provider of advanced software for research and development (R&D) organizations to securely capture, manage, share and exploit structured and unstructured data.
Our diverse customer list includes R&D driven international companies in pharmaceuticals, biotechnology, agricultural sciences, chemicals, consumer goods, energy, engineering, food and beverage, and healthcare.
Founded in 1989 and privately held until 2017, IDBS is headquartered in the United Kingdom with offices across Europe, Asia and the United States. IDBS employs over 250 staff across the world and serving over 50,000 researchers in 25 countries – including 22 of the top 25 pharmaceutical companies.
IDBS was acquired by the Danaher Group and joined their Life Sciences platform in late October 2017. IDBS will help provide the foundation for a portfolio of life sciences informatics and knowledge management solutions that will accelerate the speed of discovering, developing and producing new drugs and therapies.